Related Experiment Video
Updated: May 23, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Strategy in advanced castration-resistant prostate cancer]
Marine Gross-Goupil1, Sophie Roca, Gilles Pasticier
1CHU de Bordeaux, hôpital Saint-André, service d'oncologie médicale, 1, rue Jean-Burguet, 33075 Bordeaux, France. marine.gross-goupil@chu-bordeaux.fr
Bulletin Du Cancer
|April 24, 2012
Summary
Androgen deprivation therapy is standard for metastatic prostate cancer, but resistance develops. New agents like cabazitaxel and abiraterone acetate are revolutionizing castrate-resistant prostate cancer treatment.
Area of Science:
- Oncology
- Urology
Background:
- Androgen deprivation therapy (ADT) is the cornerstone for metastatic prostate cancer.
- Hormone-sensitive prostate cancer eventually progresses to castrate-resistant prostate cancer (CRPC).
- Significant advancements have redefined CRPC management since 2004.
Purpose of the Study:
- To review the evolving therapeutic landscape for castrate-resistant prostate cancer.
- To highlight recent breakthroughs and emerging treatment strategies.
- To discuss the role of novel agents and supportive care.
Main Methods:
- Review of current literature and clinical trial data.
- Analysis of treatment outcomes for various therapeutic modalities.
- Discussion of emerging drug classes and their clinical implications.
Main Results:
- Chemotherapy (docetaxel) remains a key option for aggressive CRPC.
- Newer agents, including cabazitaxel and abiraterone acetate, show promise post-chemotherapy.
- Denosumab offers improved bone metastasis management over zoledronic acid.
Conclusions:
- The management of CRPC has undergone a revolution with novel therapeutic options.
- Future research focuses on optimizing sequencing and combination therapies.
- Continued development is crucial for improving outcomes in advanced prostate cancer.
